54536-22-0

Basic information

• Product Name: N-(4-methoxy-d₃-phenyl)acetamide
• Synonyms: N-(4-methoxy-d₃-phenyl)acetamide
• CAS NO: 54536-22-0
• Molecular Weight: 168.168
• Mol File: 54536-22-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-(4-methoxy-d₃-phenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-methoxy-d₃-phenyl)acetamide(54536-22-0)
• EPA Substance Registry System: N-(4-methoxy-d₃-phenyl)acetamide(54536-22-0)

Safety Data

• Hazardous Substances Data: 54536-22-0(Hazardous Substances Data)

Upstream product

• 26053-96-3 4-acetoxy-4'-methoxyazobenzene 
• 865-50-9 iodomethane-d3 
• 103-90-2 4-acetaminophenol 
• 123-30-8 4-amino-phenol 
• 15199-43-6 d6-dimethyl sulfate 
• 108-24-7 acetic anhydride 

Downstream Products

• 922730-95-8 2-nitro-4-trideuteriomethoxyaniline 
• 180626-23-7 4-([D₃]methoxy)aniline 
• 922730-96-9 d3-2-nitro-4-methoxy acetanilide 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS

The invention provides compounds of formula (16) and (17); and salts thereof, as well as compositions comprising such compounds and salts, complexes comprising such compounds and salts, and methods for treating cancer, inhibiting BMI1 expression, or treating Huntington's disease using such compounds, salts, and complexes. The compounds, salts, and complexes have potency, permeability, and oral bioavailability that make them particularly useful, for example, for the treatment of glioblastoma.

LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS ANS THEIR METHODS OF USE

Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.

Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties

Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.